#Canada #Montreal #ExCellThera #Zemcelpro® #Cordex Biologics

Zemcelpro®: New Hope in High-Risk Blood Cancer Treatments

In an exciting development for patients suffering from high and very high-risk blood cancers, ExCellThera Inc. has announced impressive outcomes regarding Zemcelpro® (dorocubicel). This innovative therapy is based on blood stem cell expansion technology and has shown remarkable survival rates among patients with acute leukaemias and myelodysplastic syndromes (MDS). The groundbreaking results from phase 2 studies are set to be unveiled during the 2026 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 23, 2026, in Madrid, Spain.

Overview of Zemcelpro®

Zemcelpro®, also referred to as the cell therapy UM171, was evaluated in two phase 2 clinical studies involving 60 adult participants diagnosed with severe forms of acute leukemias and high-risk myelodysplastic syndromes. This patient cohort is notorious for its poor prognoses and high relapse rates following traditional stem cell transplants. Remarkably, the studies demonstrated overall survival (OS) rates of 63.7% after 24 months of treatment with Zemcelpro®. Furthermore, progression-free survival (PFS) and relapse-free survival (RFS) rates were reported to be 57.0% and 60%, respectively.

The study highlighted a stark contrast in outcomes based on patient age, with those under the age of 43 showcasing zero non-relapse mortality (NRM). Specifically, in this younger demographic, the 24-month OS and PFS rates soared to 82.8% and 79.3%, signaling a significant advancement in treatment efficacy for high-risk patients that typically exhibit median survival probabilities of just 25-40% with conventional therapies.

Study Details and Findings

The findings to be presented at EBMT have been eagerly anticipated as they challenge existing expectations surrounding treatment for these challenging conditions. The cumulative incidences of relapse and NRM were reported at 22.5% and 20.5%, respectively. The data underscored that age remained the most crucial predictor of NRM, further establishing the therapy's potential advantages for younger patients grappling with aggressive blood diseases.

In terms of complications, acute graft-versus-host disease (GVHD) of grades III–IV occurred in 20% of patients, while moderate to severe chronic GVHD was relatively rare, affecting only 7% at the two-year mark.

Dr. Guy Sauvageau, Chief Scientific Officer at ExCellThera, emphasized the significance of these results, stating, “This marks a remarkable and clinically relevant advancement for Zemcelpro® considering the historical overall survival of similar patients remains a dismal statistic.”

Implications for Future Treatment

In light of these promising findings, David Millette, CEO of ExCellThera, expressed optimism for the future of Zemcelpro®, suggesting that it could redefine standard care for those facing high-risk blood cancers. As therapies evolve, the potential impact on treatment paradigms is profound, particularly for patients who currently face disheartening outcomes with conventional methods.

Zemcelpro® is a cryopreserved hematopoietic stem cell transplant product comprised of expanded CD34+ cells (dorocubicel) and non-expanded CD34- cells sourced from the same cord blood unit. This dual-component strategy harnesses cutting-edge cell expansion techniques, making it a pioneering intervention amidst ongoing clinical trials across North America and Europe.

Conclusion

As ExCellThera prepares to share the full scope of these astonishing results at the EBMT 2026, the medical community watches closely. The capabilities of Zemcelpro® offer newfound hope and could potentially scale new heights within the realm of blood cancer treatment. Ongoing studies and future phase 3 trials, anticipated to commence shortly, will illuminate the path forward for this innovative therapy and its role in combating some of the most formidable challenges faced by patients today.